Why the study?
Do angiotensin II receptor antagonists provide similar clinical benefits to ACE inhibitors without the adverse effect of cough in patients with chronic heart failure?
Do angiotensin II receptor antagonists provide similar clinical benefits to ACE inhibitors without the adverse effect of cough in patients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
This article discusses the theoretical rationale for using angiotensin II receptor antagonists instead of ACE inhibitors in heart failure to avoid bradykinin-induced cough.
Angiotensin II receptor antagonists for heart failure ACE inhibitors have revolutionised the treatment of chronic heart failure; however, as is often the case with drug treatment, we are remarkably ignorant of exactly how they work. Understanding the mechanisms involved is of fundamental importance because it is a major goal of pharmacological research to produce more specific drugs that act on the mechanism producing clinical benefit while having no eVect on the mechanisms producing adverse effects. This ideal scenario seems to be a possibility if we substitute angiotensin II receptor antagonist drugs for ACE inhibitors. The rather optimistic idea behind this is that most if not all of the benefits of ACE inhibitors are because of angiotensin II suppression while the main adverse eVect of ACE inhibitors (cough) is caused by bradykinin accumulation. How has practice lived up to this theory? on July 18,
No takes yet. Share an insight, caveat, or question.
Allan D. Struthers (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: